diaDexus licenses cancer test to DGX

Quest Diagnostics (DGX) exercised an option under an existing deal with diaDexus (South San Francisco, Calif.) to receive exclusive development and marketing rights to diaDexus' genomics-based colorectal cancer diagnostic, which detects Reg-4 protein, in the U.S. and certain international territories. diaDexus will receive for upfront fees and royalties, and will retain rights to develop the test for certain future markets. ...